Aomori

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· Phase 2· Source

• Active, not recruiting

  TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

  NCT05729711· Source

• Active, not recruiting

  SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

  NCT05141201· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting
• Rheumatoid arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Tezepelumab PRO Study

  NCT05922891· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· Source

• Completed

  Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

  NCT05835778· Source

• Completed

  LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

  NCT05677308· Source

• Completed

  Forxiga CKD Japan Post-Marketing Surveillance (PMS)

  NCT05306210· Source

• Completed

  Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

  NCT04872621· Source

• Completed

  Forxiga HF General Drug Use-Results Study

  NCT04865406· Source

• Completed

  FASENRA SCEI for Long-term Use

  NCT03588546· Source